1. Erdbrugger U, Groot K de (2011) Nierenschädigung durch Methotrexat? Dosisabhängigkeit, Komorbidität und Komedikation. Z Rheumatol 70(7):549–552
2. Fiehn C (2010) Methotrexate transport mechanisms: the basis for targeted drug delivery and ß-folate-receptor-specific treatment. Clin Exp Rheumatol 28(5 Suppl 61):S40–45
3. Seideman P, Muller-Suur R (1993) Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Ann Rheum Dis 52(8):613–615
4. Kremer JM, Petrillo GF, Hamilton RA (1995) Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. J Rheumatol 22(1):41–44
5. Kremer JM, Petrillo GF, Hamilton RA (1995) Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 22(1):38–40